|
|
Vol. 16.11 – 20 June, 2025
|
|
|
|
|
|
|
|
Scientists utilized a cysteine-reactive covalent ligand library in a cellular screen to identify degraders of the androgen receptor (AR) and AR-V7 in androgen-independent prostate cancer cells. [Journal of the American Chemical Society]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators systematically explored the cellular uptake of three multimodal contrast agents across prostate cancer cell lines with varying aggressiveness. [ACS Applied Materials & Interfaces]
|
|
|
|
|
|
Compared to gastrin-releasing peptide receptor – (GRPR-) patients, metastatic castration-resistant prostate cancer (mCRPC) patients with GRPR + lesions exhibited a lower median maximum PSA response rate and a shorter median progression-free survival duration following ARSI treatment. [European Journal of Nuclear Medicine and Molecular Imaging]
|
|
|
|
|
|
Advanced prostate cancer patients undergoing hormone therapy demonstrate increased arterial inflammation on FDG-PET imaging compared to non-hormonally treated controls.
[European Journal of Nuclear Medicine and Molecular Imaging]
|
|
|
|
|
|
Researchers found that oral medication of D-mannose effectively enhances the radiosensitivity of PSMA-positive murine RM1-hPSMA prostate cancer cells to targeted radioligand therapy by suppressing glucose metabolism.
[Drug Delivery and Translational Research]
|
|
|
|
|
|
To understand the role of P2X4 receptor (P2X4R) in prostate cancer (PCa) biology, particularly in PCa bone metastasis, P2X4R was knocked out in human PCa cell line PC3 cells using the CRISPR/Cas9 system. [Purinergic Signalling]
|
|
|
|
|
|
|
|
The authors summarize the latest drug treatment strategies and clinical concerns in the management of advanced prostate cancer in Japan, based on the Japanese Clinical Practice Guidelines for Prostate Cancer published in 2023. [Japanese Journal of Radiology]
|
|
|
|
|
|
|
|
Philochem AG announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialize OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. [Philochem AG]
|
|
|
|
|
|
|
|
July 27 – August 1, 2025 Barcelona, Spain
|
|
|
|
|
|
|
|
|
|
|
Ulster University – Coleraine, Northern Ireland, United Kingdom
|
|
|
|
|
|
|
Emory University – Atlanta, Georgia, United States
|
|
|
|
|
|
|
Indiana University – Bloomington, Indiana, United States
|
|
|
|
|
|
|
University of Glasgow – Glasgow, Scotland, United Kingdom
|
|
|
|
|
|
|
Johns Hopkins Medicine – Baltimore, Maryland, United States
|
|
|
|
|
|